<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624736</url>
  </required_header>
  <id_info>
    <org_study_id>2022-LCYJ-MS-25</org_study_id>
    <nct_id>NCT05624736</nct_id>
  </id_info>
  <brief_title>Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning</brief_title>
  <official_title>Artificial Intelligence Research of Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a restrospective study to establish a deep learning model based on multi-parametric&#xD;
      magnetic resonance imaging scans to predict Grade, histopathologic type and genotype of adult&#xD;
      diffuse Glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioma is a common kind of tumor in central nervous system. The pre-operative prediction of&#xD;
      grade, histopathologic type and genotype is important for treatment and management of Adult&#xD;
      diffuse Glioma patients. Right now, most of the diagnostic prediction models on glioma are&#xD;
      based on 2016 WHO central nervous system tumor guideline. The goal of this study is to&#xD;
      establish a new deep learning model to predict Grade, histopathologic type and genotype of&#xD;
      adult diffuse Glioma. We will recruit 500 patients with pathologically confirmed diagnosis of&#xD;
      Glioblastoma, Astrocytoma and Oligodendroglioma who received neurologic surgery in our&#xD;
      center. Each subject underwent pre-operative multi-parametric magnetic resonance imaging&#xD;
      scans including T1WI, T2WI, T1CE, FLAIR and DWI. Pathologic diagnosis of each patient are&#xD;
      available in pathology department. A deep learning based hierarchical diagnosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2022</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Grade</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Tumor Grade based on 2021 WHO central nervous system tumor guideline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Histologic diagnosis</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Tumor histologic diagnosis based on 2021 WHO central nervous system tumor guideline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor genotype</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Tumor genotype based on 2021 WHO central nervous system tumor guideline</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Astrocytoma</condition>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Oligodendroglioma</condition>
  <arm_group>
    <arm_group_label>Glioblastoma Group</arm_group_label>
    <description>Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Astrocytoma Group</arm_group_label>
    <description>Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oligodendroglioma Group</arm_group_label>
    <description>Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multi-parametric magnetic resonance imaging scan</intervention_name>
    <description>Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.</description>
    <arm_group_label>Astrocytoma Group</arm_group_label>
    <arm_group_label>Glioblastoma Group</arm_group_label>
    <arm_group_label>Oligodendroglioma Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pathology examination</intervention_name>
    <description>The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test</description>
    <arm_group_label>Astrocytoma Group</arm_group_label>
    <arm_group_label>Glioblastoma Group</arm_group_label>
    <arm_group_label>Oligodendroglioma Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosis of adult diffuse glioma who recevived tumor rection surgery in our&#xD;
        center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing surgery in Nanjing DrumTower Hospital between 2010.01 and 2022.05&#xD;
             with post-surgery pathological diagnosis of WHO Grade II to IV Adult Diffuse Glioma.&#xD;
&#xD;
          2. Available pre-surgery T1WI, T2WI, T1CE, FLARI and DWI MR sequences&#xD;
&#xD;
          3. No pre-surgery anti-tumor therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Poor image quality&#xD;
&#xD;
          2. Failed image preprocessing&#xD;
&#xD;
          3. Unavailable pathology data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Zhang, Master</last_name>
    <phone>13814066403</phone>
    <email>zhangxin@njglyy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiology, the Affiliated Drum Tower Hospital of Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210093</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Zhang, Master</last_name>
      <phone>13814066403</phone>
      <email>zhangxin@njglyy.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>November 13, 2022</study_first_submitted>
  <study_first_submitted_qc>November 21, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 21, 2022</last_update_submitted>
  <last_update_submitted_qc>November 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Astrocytoma</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Oligodendroglioma</keyword>
  <keyword>deep learning</keyword>
  <keyword>artificial intelligence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We don't plan to share IPD with other researches</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

